News and Trends 21 Mar 2023
Karuna Therapeutics sees positive schizophrenia trial results
Karuna Therapeutics, Inc. has announced positive topline results from its phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium) in adults with…